Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.

[1]  J. Flowers,et al.  Origins and geographic diversification of African rice (Oryza glaberrima) , 2018, bioRxiv.

[2]  G. Serio,et al.  Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array , 2017, International journal of molecular sciences.

[3]  Yusuke Nakamura,et al.  Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma , 2017, Oncoimmunology.

[4]  J. Zucman‐Rossi,et al.  Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma , 2016, Clinical Cancer Research.

[5]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[6]  E. Moses,et al.  Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. , 2015, Gene.

[7]  R. Stahel,et al.  Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors , 2015, Cell Death and Disease.

[8]  M. Meyerson,et al.  Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. , 2015, Cancer research.

[9]  D. Toncheva,et al.  Whole genome microarray analysis in non-small cell lung cancer , 2015, Biotechnology, biotechnological equipment.

[10]  B. Ghanim,et al.  Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. , 2014, American journal of respiratory and critical care medicine.

[11]  J. Bultinck,et al.  Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase , 2014, EMBO molecular medicine.

[12]  Scott D. Brown,et al.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.

[13]  J. Fletcher,et al.  Multipoint targeting of the PI3K/mTOR pathway in mesothelioma , 2014, British Journal of Cancer.

[14]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[15]  P. Dubus,et al.  FGFR3 has tumor suppressor properties in cells with epithelial phenotype , 2013, Molecular Cancer.

[16]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[17]  S. Anttila,et al.  Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos‐exposed patients , 2013, Molecular oncology.

[18]  Joaquín Dopazo,et al.  Qualimap: evaluating next-generation sequencing alignment data , 2012, Bioinform..

[19]  F. Mott.  Mesothelioma: a review. , 2012, The Ochsner journal.

[20]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[21]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[22]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[23]  John Quackenbush,et al.  Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV , 2011, Bioinform..

[24]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[25]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[26]  F. Galateau-Sallé,et al.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. , 2011, The American journal of pathology.

[27]  Y. Kondo,et al.  LATS2 is a tumor suppressor gene of malignant mesothelioma. , 2011, Cancer research.

[28]  Tsukasa Suzuki,et al.  Immunohistochemical Detection of Fibroblast Growth Factor Receptor 3 in Human Breast Cancer: Correlation with Clinicopathological/Molecular Parameters and Prognosis , 2010, Pathobiology.

[29]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[30]  K. Huse,et al.  Haplotyping and copy number estimation of the highly polymorphic human beta-defensin locus on 8p23 by 454 amplicon sequencing , 2010, BMC Genomics.

[31]  Y. Kanai,et al.  Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non‐muscle invasive bladder cancer , 2010, Cancer science.

[32]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[33]  Michael Hiller,et al.  Genetic Variants of the Copy Number Polymorphic β-Defensin Locus Are Associated with Sporadic Prostate Cancer , 2008, Tumor Biology.

[34]  H. Tagawa,et al.  Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32 , 2007, Cancer science.

[35]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[36]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[37]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[40]  A. Musk,et al.  Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions , 1991, International journal of cancer.

[41]  J. Wagner,et al.  Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 1960, British journal of industrial medicine.

[42]  Zhiyong Liang,et al.  Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. , 2015, International journal of clinical and experimental pathology.

[43]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .